Ziccum CEO Analyst interview part 2

MFN Publicerad: 29 Aug 2023 08:30

In part two of her Analyst interview CEO Ann Gidner offers a deep dive into the second of the company’s recent milestone Feasibility agreements plus an analysis of mRNA, why it is generating such historic levels of investment, and how Ziccum’s unique drying technology LaminarPace could be a key enabler in unlocking its potential.

Watch Ziccum CEO Ann Gidner in the second part of her extended interview with Eucaps analyst Jonathan Furelid HERE.

Or visit Ziccum’s company page on Eucaps HERE.

About Ziccum

Ziccum is developing LaminarPaceTM, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Börskollen

För dig med koll på börsen

Pressmeddelande

Ziccum CEO Analyst interview part 2

Bifogade filer

Nyheter om Ziccum

Läses av andra just nu

Om aktien Ziccum

Senaste nytt